Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Pharmacopsychiatry ; 55(1): 24-29, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34875696

RESUMO

Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer's disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer's disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications.


Assuntos
Doença de Alzheimer , COVID-19 , Neoplasias , Doença de Alzheimer/tratamento farmacológico , Reposicionamento de Medicamentos , Humanos , Inflamação/tratamento farmacológico , Neoplasias/tratamento farmacológico , Neuroproteção , Pandemias , SARS-CoV-2 , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA